LegalizeSupply and Appropriation (Anticipation and Adjustments) Act 2024
Vote on Account for 2024-25
Vote on account for 2024-25
1
- (1) The use of resources for the year ending with 31 March 2025 is authorised up to the amount of £472,512,874,000.
- (2) Of the amount authorised by subsection (1)—
- (a) £373,672,234,000 is authorised for use for current purposes, and
- (b) £98,840,640,000 is authorised for use for capital purposes.
- (3) The Treasury may—
- (a) issue money out of the Consolidated Fund, and
- (b) apply it in the year ending with 31 March 2025 for expenditure authorised by Parliament,
up to the amount of £386,454,679,000.
Supplementary provision for 2023-24
Authorisation of supplementary provision for 2023-24
2
- (1) The amount up to which the authorisation was conferred for the use of resources for the year ending with 31 March 2024 is to be treated as further increased by £18,577,452,000.
- (2) In relation to the further amount treated as authorised by subsection (1)—
- (a) the amount up to which there is authorisation for use for current purposes is to be treated as further increased by £29,619,818,000, and
- (b) the amount up to which there is authorisation for use for capital purposes is to be treated as reduced by £11,042,366,000.
- (3) The amount up to which authorisation was conferred on the Treasury—
- (a) to issue money out of the Consolidated Fund, and
- (b) to apply it in the year ending with 31 March 2024 for expenditure authorised by Parliament,
is to be treated as further increased by £10,943,718,000.
- (4) The increases and reduction for which this section provides are to be treated as having had effect from the beginning of 1 April 2023.
Appropriation of supplementary provision for 2023-24
3
- (1) For the purposes of—
- (a) appropriating the amount of resources the use of which for the year ending with 31 March 2024 is authorised by section 2(1), and
- (b) appropriating the amount of money the issue of which out of the Consolidated Fund is authorised by section 2(3),
the Main Estimates Act 2023 is to be treated as having effect with the adjustments provided for in Schedule 1 to this Act.
- (2) Schedule 1 specifies the amounts by which adjustments are to be treated as made to the amounts originally specified in the Scheduled Estimates in the Main Estimates Act 2023.
- (3) For the purpose of making the adjustments in Schedule 1—
- (a) a negative adjustment has effect to reduce an amount of authorised expenditure and, where applied to an estimated surplus (which is expressed as if it were itself a negative amount), increases the amount of the surplus, and
- (b) a positive adjustment has effect to increase an amount of authorised expenditure and, where applied to an estimated surplus, reduces it.
- (4) Accordingly—
- (a) where an adjustment by a negative amount of more than the amount itself is made to an amount of authorised expenditure, what results is an estimated surplus, and
- (b) where an adjustment by a positive amount of more than the amount itself is made to the amount of an estimated surplus, what results is an amount of authorised expenditure.
- (5) Where, in Schedule 1, a description of matters to which expenditure may relate or from which income may arise (“description A”) differs from the description contained in the corresponding part of the Scheduled Estimates in the Main Estimates Act 2023 (“description B”), Schedule 1 has effect for adjusting that corresponding part by substituting description A for description B.
- (6) Where, in relation to a department, other person or service to which a Scheduled Estimate in the Main Estimates Act 2023 relates, Schedule 1 contains a new description of matters to which expenditure may relate or from which income may arise, Schedule 1 has effect for adjusting that Scheduled Estimate by treating the new description as included in it.
- (7) In this section—
- “estimated surplus” has the same meaning as in the Main Estimates Act 2023;
- “Main Estimates Act 2023” means the Supply and Appropriation (Main Estimates) Act 2023.
- (8) The adjustments made by virtue of this section are to be treated as having had effect from the beginning of 1 April 2023.
Excesses for 2022-23
Authorisation of excesses for 2022-23
4
- (1) The amount up to which authorisation was conferred for the use of resources for the year ending with 31 March 2023 is to be treated as further increased, for the purpose of making good excesses, by £946,445,000.
- (2) The further amount treated as authorised by subsection (1) is to be treated as authorised for use for current purposes.
- (3) The increases for which this section provides are to be treated as having had effect from the beginning of 1 April 2022.
Appropriation of excesses for 2022-23
5
- (1) For the purpose of appropriating the amount of resources the use of which for the year ending with 31 March 2023 is authorised by section 4(1), the Main Estimates Act 2022 is treated as having effect with the adjustments provided for in Schedule 2 to this Act.
- (2) Schedule 2 specifies the amounts by which adjustments are to be treated as made to the amounts specified in the Scheduled Estimates in the Main Estimates Act 2022 and to the amounts treated as so specified.
- (3) For the purpose of making the adjustments in Schedule 2 an adjustment has effect to increase an amount of authorised expenditure and, where applied to an estimated surplus, reduces it.
- (4) Accordingly, where an adjustment of more than the amount itself is made to the amount of an estimated surplus, what results is an amount of authorised expenditure.
- (5) Where, in Schedule 2, a description of matters to which expenditure may relate or from which income may arise (“description A”) differs from the description contained in the corresponding part of the Scheduled Estimates in the Main Estimates Act 2022 (“description B”), Schedule 2 has effect for adjusting that corresponding part by substituting description A for description B.
- (6) Where, in relation to a department, other person or service to which a Scheduled Estimate in the Main Estimates Act 2022 relates, Schedule 2 contains a new description of matters to which expenditure may relate or from which income may arise, Schedule 2 has effect for adjusting that Scheduled Estimate by treating the new description as included in it.
- (7) In this section—
- “estimated surplus” has the same meaning as in the Main Estimates Act 2022;
- “Main Estimates Act 2022” means the Supply and Appropriation (Main Estimates) Act 2022 as it is treated as having effect in consequence of the adjustments made by virtue of the Supply and Appropriation (Adjustments) Act 2022 and the Supply and Appropriation (Anticipation and Adjustments) Act 2023.
- (8) The adjustments made by virtue of this section are to be treated as having had effect from the beginning of 1 April 2022.
General
Short title
6
This Act may be cited as the Supply and Appropriation (Anticipation and Adjustments) Act 2024.
Schedule 1
1
- (1) In this Schedule, where an asterisk (*) appears at the beginning of a description of matters to which expenditure may relate, or from which income may arise, the description is a description which was not included in the Schedule to the Supply and Appropriation (Main Estimates) Act 2023 as originally enacted.
- (2) Text which follows an asterisk (*) is added by this Schedule.
| Estimate | Net resources authorised for current purposes | Net resources authorised for capital purposes | Net Cash Requirement |
|---|---|---|---|
| Estimate | (£) | (£) | (£) |
| Department of Health and Social Care | Department of Health and Social Care | Department of Health and Social Care | Department of Health and Social Care |
| Departmental Expenditure Limit | 3,788,392,000 | -1,098,955,000 | |
| Annually Managed Expenditure | -13,151,625,000 | 1,000 | |
| Non-budget Expenditure | 0 | ||
| Net Cash Requirement | -4,984,091,000 | ||
| Total | -9,363,233,000 | -1,098,954,000 | -4,984,091,000 |
| Departmental Expenditure Limit Expenditure arising from: Revenue (administration and programme) and capital expenditure of the Department of Health and Social Care and other designated bodies, including NHS England (including Integrated Care Boards), NHS Providers, Special Health Authorities, Executive Non-Departmental Public Bodies, the UK Health Security Agency and the Medicines and Healthcare products Regulatory Agency. Health and social service expenditure to and on behalf of the NHS including the settlement of claims for personal injury and clinical negligence, local authorities and other national bodies. Local government services, prison health services, medical, scientific and technical services, services for disabled persons, education and training, grants to voluntary organisations and other bodies, information services, breast implant registry, Healthy Start programme, health promotion activities, research and development and expenditure incurred in relation to life sciences. Governmental response to the coronavirus Covid-19 pandemic. This includes, but is not exhaustive: NHS Test and Trace, personal protective equipment, Covid-19 medicines, treatments and equipment and the supply, distribution and deployment of Covid-19 vaccines and associated activities. Non-Departmental Public Bodies' expenditure on health and social care protection, training and regulation functions. Expenditure to charitable trusts and companies providing financial support and other relief to persons who contracted HIV and Hepatitis C through receiving NHS treatment. Forming, investing in or providing loans or guarantees to companies that will provide facilities or services to the NHS. Services provided to or on behalf of devolved governments and other government departments. Medical treatment given to people from the United Kingdom in the European Economic Area and other countries. Subsidies and grants to public corporations and local authorities, payments to local authorities for use in local area agreements. Official Development Assistance projects and activities. Subscriptions to international organisations and international and commercial facilitation relating to healthcare. Payments for services incurred by other government departments, including expenditure on behalf of the Department for Work and Pensions. Associated depreciation and any other non-cash costs (including provisions, impairments and impairment of receivables). Expenditure incurred in relation to the Covid-19 Vaccine Taskforce. Income arising from: Charges for accommodation, sales of goods and services, income generation schemes. Local authorities under joint financing arrangements. Fines and penalty notices. Medical and dental education levy. Licensing of software, use of NHS logo, settlement of legal claims, dividends and interest from loans and investments, intellectual property, research and development, prescription fraud charges, NHS prescriptions, dental and ophthalmic fraud charges. Recoveries from patients in respect of incorrect claims for eligibility including for NHS treatment and general ophthalmic services. Payments from manufacturers or suppliers of medicinal products to control the cost of health service medicines and purchasing and supply agency arrangements. Sales of medicines, vaccines, antivenoms, antitoxins and equipment, premiums applied to the sale of stock. Income from the Scottish Government, the Welsh Government, Northern Ireland, Channel Islands and Isle of Man for services provided for devolved or reserved work. Provision of policy and advice to other countries and care trusts. Maintenance of the National Joint Registry, conference and meeting events, prison health services, contributions to substance misuse funding, use of radio communication bandwidth. Income secured by counter fraud services from all sources. Administration income from seconded officers, cost of legal proceedings, staff telephone calls, European fast stream programme. Recoveries and income from other government departments, recoveries and income from ALBs (including capital and grants), special health authorities and NHS bodies. Selling services into wider markets and open government, payment by commercial tenants in DHSC buildings and compensation income. Licence fees and royalties, sales of publications, contributions by members of the public, insurance claims and social exclusion programmes. Other European Economic Area countries for NHS treatment of their residents. Income collected for the immigration health surcharge. Sales of subsidised dried milk. Income from the European Union. Contributions from the mobile phone industry, charitable contributions, refunds from voluntary organisations. Contributions to local authority grant schemes. Contributions and refunds towards communication campaigns contracts. Penalty charges, interest and dividends on trading fund loans. Income collected on behalf of health innovation and education clusters. Income received from the sale of capital assets. Income received from the disposal of financial assets. Income associated with the acquisition of assets. Income arising from Governmental response to the coronavirus Covid-19 pandemic. Income arising from activities in relation to the Covid-19 Vaccine Taskforce and Covid-19 Antiviral Taskforce. Annually Managed Expenditure Expenditure arising from: Revenue and capital expenditure for hospital financing under Credit Guarantee Finance. Provisions and other non-cash costs, of the Department of Health and Social Care and other designated bodies, including NHS England (including Integrated Care Boards), NHS Providers, Special Health Authorities, Executive Non-Departmental Public Bodies, the UK Health Security Agency and the Medicines and Healthcare products Regulatory Agency. Governmental response to the coronavirus Covid-19 pandemic. | Departmental Expenditure Limit Expenditure arising from: Revenue (administration and programme) and capital expenditure of the Department of Health and Social Care and other designated bodies, including NHS England (including Integrated Care Boards), NHS Providers, Special Health Authorities, Executive Non-Departmental Public Bodies, the UK Health Security Agency and the Medicines and Healthcare products Regulatory Agency. Health and social service expenditure to and on behalf of the NHS including the settlement of claims for personal injury and clinical negligence, local authorities and other national bodies. Local government services, prison health services, medical, scientific and technical services, services for disabled persons, education and training, grants to voluntary organisations and other bodies, information services, breast implant registry, Healthy Start programme, health promotion activities, research and development and expenditure incurred in relation to life sciences. Governmental response to the coronavirus Covid-19 pandemic. This includes, but is not exhaustive: NHS Test and Trace, personal protective equipment, Covid-19 medicines, treatments and equipment and the supply, distribution and deployment of Covid-19 vaccines and associated activities. Non-Departmental Public Bodies' expenditure on health and social care protection, training and regulation functions. Expenditure to charitable trusts and companies providing financial support and other relief to persons who contracted HIV and Hepatitis C through receiving NHS treatment. Forming, investing in or providing loans or guarantees to companies that will provide facilities or services to the NHS. Services provided to or on behalf of devolved governments and other government departments. Medical treatment given to people from the United Kingdom in the European Economic Area and other countries. Subsidies and grants to public corporations and local authorities, payments to local authorities for use in local area agreements. Official Development Assistance projects and activities. Subscriptions to international organisations and international and commercial facilitation relating to healthcare. Payments for services incurred by other government departments, including expenditure on behalf of the Department for Work and Pensions. Associated depreciation and any other non-cash costs (including provisions, impairments and impairment of receivables). Expenditure incurred in relation to the Covid-19 Vaccine Taskforce. Income arising from: Charges for accommodation, sales of goods and services, income generation schemes. Local authorities under joint financing arrangements. Fines and penalty notices. Medical and dental education levy. Licensing of software, use of NHS logo, settlement of legal claims, dividends and interest from loans and investments, intellectual property, research and development, prescription fraud charges, NHS prescriptions, dental and ophthalmic fraud charges. Recoveries from patients in respect of incorrect claims for eligibility including for NHS treatment and general ophthalmic services. Payments from manufacturers or suppliers of medicinal products to control the cost of health service medicines and purchasing and supply agency arrangements. Sales of medicines, vaccines, antivenoms, antitoxins and equipment, premiums applied to the sale of stock. Income from the Scottish Government, the Welsh Government, Northern Ireland, Channel Islands and Isle of Man for services provided for devolved or reserved work. Provision of policy and advice to other countries and care trusts. Maintenance of the National Joint Registry, conference and meeting events, prison health services, contributions to substance misuse funding, use of radio communication bandwidth. Income secured by counter fraud services from all sources. Administration income from seconded officers, cost of legal proceedings, staff telephone calls, European fast stream programme. Recoveries and income from other government departments, recoveries and income from ALBs (including capital and grants), special health authorities and NHS bodies. Selling services into wider markets and open government, payment by commercial tenants in DHSC buildings and compensation income. Licence fees and royalties, sales of publications, contributions by members of the public, insurance claims and social exclusion programmes. Other European Economic Area countries for NHS treatment of their residents. Income collected for the immigration health surcharge. Sales of subsidised dried milk. Income from the European Union. Contributions from the mobile phone industry, charitable contributions, refunds from voluntary organisations. Contributions to local authority grant schemes. Contributions and refunds towards communication campaigns contracts. Penalty charges, interest and dividends on trading fund loans. Income collected on behalf of health innovation and education clusters. Income received from the sale of capital assets. Income received from the disposal of financial assets. Income associated with the acquisition of assets. Income arising from Governmental response to the coronavirus Covid-19 pandemic. Income arising from activities in relation to the Covid-19 Vaccine Taskforce and Covid-19 Antiviral Taskforce. Annually Managed Expenditure Expenditure arising from: Revenue and capital expenditure for hospital financing under Credit Guarantee Finance. Provisions and other non-cash costs, of the Department of Health and Social Care and other designated bodies, including NHS England (including Integrated Care Boards), NHS Providers, Special Health Authorities, Executive Non-Departmental Public Bodies, the UK Health Security Agency and the Medicines and Healthcare products Regulatory Agency. Governmental response to the coronavirus Covid-19 pandemic. | Departmental Expenditure Limit Expenditure arising from: Revenue (administration and programme) and capital expenditure of the Department of Health and Social Care and other designated bodies, including NHS England (including Integrated Care Boards), NHS Providers, Special Health Authorities, Executive Non-Departmental Public Bodies, the UK Health Security Agency and the Medicines and Healthcare products Regulatory Agency. Health and social service expenditure to and on behalf of the NHS including the settlement of claims for personal injury and clinical negligence, local authorities and other national bodies. Local government services, prison health services, medical, scientific and technical services, services for disabled persons, education and training, grants to voluntary organisations and other bodies, information services, breast implant registry, Healthy Start programme, health promotion activities, research and development and expenditure incurred in relation to life sciences. Governmental response to the coronavirus Covid-19 pandemic. This includes, but is not exhaustive: NHS Test and Trace, personal protective equipment, Covid-19 medicines, treatments and equipment and the supply, distribution and deployment of Covid-19 vaccines and associated activities. Non-Departmental Public Bodies' expenditure on health and social care protection, training and regulation functions. Expenditure to charitable trusts and companies providing financial support and other relief to persons who contracted HIV and Hepatitis C through receiving NHS treatment. Forming, investing in or providing loans or guarantees to companies that will provide facilities or services to the NHS. Services provided to or on behalf of devolved governments and other government departments. Medical treatment given to people from the United Kingdom in the European Economic Area and other countries. Subsidies and grants to public corporations and local authorities, payments to local authorities for use in local area agreements. Official Development Assistance projects and activities. Subscriptions to international organisations and international and commercial facilitation relating to healthcare. Payments for services incurred by other government departments, including expenditure on behalf of the Department for Work and Pensions. Associated depreciation and any other non-cash costs (including provisions, impairments and impairment of receivables). Expenditure incurred in relation to the Covid-19 Vaccine Taskforce. Income arising from: Charges for accommodation, sales of goods and services, income generation schemes. Local authorities under joint financing arrangements. Fines and penalty notices. Medical and dental education levy. Licensing of software, use of NHS logo, settlement of legal claims, dividends and interest from loans and investments, intellectual property, research and development, prescription fraud charges, NHS prescriptions, dental and ophthalmic fraud charges. Recoveries from patients in respect of incorrect claims for eligibility including for NHS treatment and general ophthalmic services. Payments from manufacturers or suppliers of medicinal products to control the cost of health service medicines and purchasing and supply agency arrangements. Sales of medicines, vaccines, antivenoms, antitoxins and equipment, premiums applied to the sale of stock. Income from the Scottish Government, the Welsh Government, Northern Ireland, Channel Islands and Isle of Man for services provided for devolved or reserved work. Provision of policy and advice to other countries and care trusts. Maintenance of the National Joint Registry, conference and meeting events, prison health services, contributions to substance misuse funding, use of radio communication bandwidth. Income secured by counter fraud services from all sources. Administration income from seconded officers, cost of legal proceedings, staff telephone calls, European fast stream programme. Recoveries and income from other government departments, recoveries and income from ALBs (including capital and grants), special health authorities and NHS bodies. Selling services into wider markets and open government, payment by commercial tenants in DHSC buildings and compensation income. Licence fees and royalties, sales of publications, contributions by members of the public, insurance claims and social exclusion programmes. Other European Economic Area countries for NHS treatment of their residents. Income collected for the immigration health surcharge. Sales of subsidised dried milk. Income from the European Union. Contributions from the mobile phone industry, charitable contributions, refunds from voluntary organisations. Contributions to local authority grant schemes. Contributions and refunds towards communication campaigns contracts. Penalty charges, interest and dividends on trading fund loans. Income collected on behalf of health innovation and education clusters. Income received from the sale of capital assets. Income received from the disposal of financial assets. Income associated with the acquisition of assets. Income arising from Governmental response to the coronavirus Covid-19 pandemic. Income arising from activities in relation to the Covid-19 Vaccine Taskforce and Covid-19 Antiviral Taskforce. Annually Managed Expenditure Expenditure arising from: Revenue and capital expenditure for hospital financing under Credit Guarantee Finance. Provisions and other non-cash costs, of the Department of Health and Social Care and other designated bodies, including NHS England (including Integrated Care Boards), NHS Providers, Special Health Authorities, Executive Non-Departmental Public Bodies, the UK Health Security Agency and the Medicines and Healthcare products Regulatory Agency. Governmental response to the coronavirus Covid-19 pandemic. | Departmental Expenditure Limit Expenditure arising from: Revenue (administration and programme) and capital expenditure of the Department of Health and Social Care and other designated bodies, including NHS England (including Integrated Care Boards), NHS Providers, Special Health Authorities, Executive Non-Departmental Public Bodies, the UK Health Security Agency and the Medicines and Healthcare products Regulatory Agency. Health and social service expenditure to and on behalf of the NHS including the settlement of claims for personal injury and clinical negligence, local authorities and other national bodies. Local government services, prison health services, medical, scientific and technical services, services for disabled persons, education and training, grants to voluntary organisations and other bodies, information services, breast implant registry, Healthy Start programme, health promotion activities, research and development and expenditure incurred in relation to life sciences. Governmental response to the coronavirus Covid-19 pandemic. This includes, but is not exhaustive: NHS Test and Trace, personal protective equipment, Covid-19 medicines, treatments and equipment and the supply, distribution and deployment of Covid-19 vaccines and associated activities. Non-Departmental Public Bodies' expenditure on health and social care protection, training and regulation functions. Expenditure to charitable trusts and companies providing financial support and other relief to persons who contracted HIV and Hepatitis C through receiving NHS treatment. Forming, investing in or providing loans or guarantees to companies that will provide facilities or services to the NHS. Services provided to or on behalf of devolved governments and other government departments. Medical treatment given to people from the United Kingdom in the European Economic Area and other countries. Subsidies and grants to public corporations and local authorities, payments to local authorities for use in local area agreements. Official Development Assistance projects and activities. Subscriptions to international organisations and international and commercial facilitation relating to healthcare. Payments for services incurred by other government departments, including expenditure on behalf of the Department for Work and Pensions. Associated depreciation and any other non-cash costs (including provisions, impairments and impairment of receivables). Expenditure incurred in relation to the Covid-19 Vaccine Taskforce. Income arising from: Charges for accommodation, sales of goods and services, income generation schemes. Local authorities under joint financing arrangements. Fines and penalty notices. Medical and dental education levy. Licensing of software, use of NHS logo, settlement of legal claims, dividends and interest from loans and investments, intellectual property, research and development, prescription fraud charges, NHS prescriptions, dental and ophthalmic fraud charges. Recoveries from patients in respect of incorrect claims for eligibility including for NHS treatment and general ophthalmic services. Payments from manufacturers or suppliers of medicinal products to control the cost of health service medicines and purchasing and supply agency arrangements. Sales of medicines, vaccines, antivenoms, antitoxins and equipment, premiums applied to the sale of stock. Income from the Scottish Government, the Welsh Government, Northern Ireland, Channel Islands and Isle of Man for services provided for devolved or reserved work. Provision of policy and advice to other countries and care trusts. Maintenance of the National Joint Registry, conference and meeting events, prison health services, contributions to substance misuse funding, use of radio communication bandwidth. Income secured by counter fraud services from all sources. Administration income from seconded officers, cost of legal proceedings, staff telephone calls, European fast stream programme. Recoveries and income from other government departments, recoveries and income from ALBs (including capital and grants), special health authorities and NHS bodies. Selling services into wider markets and open government, payment by commercial tenants in DHSC buildings and compensation income. Licence fees and royalties, sales of publications, contributions by members of the public, insurance claims and social exclusion programmes. Other European Economic Area countries for NHS treatment of their residents. Income collected for the immigration health surcharge. Sales of subsidised dried milk. Income from the European Union. Contributions from the mobile phone industry, charitable contributions, refunds from voluntary organisations. Contributions to local authority grant schemes. Contributions and refunds towards communication campaigns contracts. Penalty charges, interest and dividends on trading fund loans. Income collected on behalf of health innovation and education clusters. Income received from the sale of capital assets. Income received from the disposal of financial assets. Income associated with the acquisition of assets. Income arising from Governmental response to the coronavirus Covid-19 pandemic. Income arising from activities in relation to the Covid-19 Vaccine Taskforce and Covid-19 Antiviral Taskforce. Annually Managed Expenditure Expenditure arising from: Revenue and capital expenditure for hospital financing under Credit Guarantee Finance. Provisions and other non-cash costs, of the Department of Health and Social Care and other designated bodies, including NHS England (including Integrated Care Boards), NHS Providers, Special Health Authorities, Executive Non-Departmental Public Bodies, the UK Health Security Agency and the Medicines and Healthcare products Regulatory Agency. Governmental response to the coronavirus Covid-19 pandemic. |
| Estimate | Net resources authorised for current purposes | Net resources authorised for capital purposes | Net Cash Requirement |
| --- | --- | --- | --- |
| Estimate | (£) | (£) | (£) |
| Department for Education | Department for Education | Department for Education | Department for Education |
| Departmental Expenditure Limit | 18,620,300,000 | -257,590,000 | |
| Annually Managed Expenditure | 2,377,348,000 | -46,982,000 | |
| Non-budget Expenditure | 0 | ||
| Net Cash Requirement | -912,367,000 | ||
| Total | 20,997,648,000 | -304,572,000 | -912,367,000 |
Reading this document does not replace reading the official text published on legislation.gov.uk. Contains public sector information licensed under the Open Government Licence v3.0. We assume no responsibility for any inaccuracies arising from the conversion of the original CLML XML to this format.
This text is published under legislation.gov.uk's own terms of reuse, not a Legalize or public-domain licence.
legislation.gov.uk
Open Government Licence v3.0 (attribution required)
© Crown and database right. Derived from content available under the Open Government Licence v3.0 from legislation.gov.uk.